291 related articles for article (PubMed ID: 25037116)
1. Predictive and prognostic value of circulating endothelial cells in non-small cell lung cancer patients treated with standard chemotherapy.
Najjar F; Alammar M; Bachour M; Almalla N; Altahan M; Alali A; Al-Massarani G
J Cancer Res Clin Oncol; 2015 Jan; 141(1):119-25. PubMed ID: 25037116
[TBL] [Abstract][Full Text] [Related]
2. Circulating endothelial cells for evaluation of tumor response in non-small cell lung cancer patients receiving first-line chemotherapy.
Najjar F; Al-Massarani G; Banat I; Alammar M
Int J Biol Markers; 2015 Nov; 30(4):e374-81. PubMed ID: 26109363
[TBL] [Abstract][Full Text] [Related]
3. Vitamin D receptor genetic variants are associated with chemotherapy response and prognosis in patients with advanced non-small-cell lung cancer.
Xiong L; Cheng J; Gao J; Wang J; Liu X; Wang L
Clin Lung Cancer; 2013 Jul; 14(4):433-9. PubMed ID: 23522953
[TBL] [Abstract][Full Text] [Related]
4. Clinical outcome of cisplatin-based chemotherapy is associated with the polymorphisms of GSTP1 and XRCC1 in advanced non-small cell lung cancer patients.
Deng JH; Deng J; Shi DH; Ouyang XN; Niu PG
Clin Transl Oncol; 2015 Sep; 17(9):720-6. PubMed ID: 26033426
[TBL] [Abstract][Full Text] [Related]
5. Gemcitabine and vinorelbine followed by weekly docetaxel in patients with advanced non-small-cell lung cancer: a phase II trial of sequential chemotherapy.
Cobo Dols M; Villar Chamorro E; Alés Díaz I; Gil Calle S; Alcalde García J; Gutiérrez Calderón V; Carabantes Ocón F; Montesa Pino A; Bretón García JJ; Benavides Orgaz M
Clin Transl Oncol; 2006 Oct; 8(10):742-9. PubMed ID: 17074673
[TBL] [Abstract][Full Text] [Related]
6. Randomized control study of nedaplatin or cisplatin concomitant with other chemotherapy in the treatment of advanced non-small cell lung cancer.
Li CH; Liu MY; Liu W; Li DD; Cai L
Asian Pac J Cancer Prev; 2014; 15(2):731-6. PubMed ID: 24568487
[TBL] [Abstract][Full Text] [Related]
7. Heterozygote advantage of methylenetetrahydrofolate reductase polymorphisms on clinical outcomes in advanced non-small cell lung cancer (NSCLC) patients treated with platinum-based chemotherapy.
Li X; Shao M; Wang S; Zhao X; Chen H; Qian J; Song X; Wang J; Jin L; Wu J; Li Q; Bai C; Han B; Gao Z; Lu D
Tumour Biol; 2014 Nov; 35(11):11159-70. PubMed ID: 25104092
[TBL] [Abstract][Full Text] [Related]
8. Genetic variants in the PI3K/PTEN/AKT/mTOR pathway predict platinum-based chemotherapy response of advanced non-small cell lung cancers in a Chinese population.
Xu JL; Wang ZW; Hu LM; Yin ZQ; Huang MD; Hu ZB; Shen HB; Shu YQ
Asian Pac J Cancer Prev; 2012; 13(5):2157-62. PubMed ID: 22901187
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of bevacizumab, cisplatin, and docetaxel plus maintenance bevacizumab as first-line treatment for patients with advanced non-squamous non-small-cell lung cancer combined with exploratory analysis of circulating endothelial cells: Thoracic Oncology Research Group (TORG)1016.
Ikeda S; Kato T; Ogura T; Sekine A; Oda T; Masuda N; Igawa S; Katono K; Otani S; Yamada K; Saito H; Kondo T; Hosomi Y; Nakahara Y; Nishikawa M; Utumi K; Misumi Y; Yamanaka T; Sakamaki K; Okamoto H
BMC Cancer; 2018 Mar; 18(1):241. PubMed ID: 29499653
[TBL] [Abstract][Full Text] [Related]
10. Circulating endothelial cells in non-small cell lung cancer patients treated with carboplatin and paclitaxel.
Kawaishi M; Fujiwara Y; Fukui T; Kato T; Yamada K; Ohe Y; Kunitoh H; Sekine I; Yamamoto N; Nokihara H; Watabe T; Shimoda Y; Arao T; Nishio K; Tamura T; Koizumi F
J Thorac Oncol; 2009 Feb; 4(2):208-13. PubMed ID: 19179898
[TBL] [Abstract][Full Text] [Related]
11. Can determination of circulating endothelial cells and serum caspase-cleaved CK18 predict for response and survival in patients with advanced non-small-cell lung cancer receiving endostatin and paclitaxel-carboplatin chemotherapy? a retrospective study.
Chu TQ; Ding H; Garfield DH; Gu AQ; Pei J; Du WD; Han BH
J Thorac Oncol; 2012 Dec; 7(12):1781-1789. PubMed ID: 23154549
[TBL] [Abstract][Full Text] [Related]
12. The role of histology with common first-line regimens for advanced non-small cell lung cancer: a brief report of the retrospective analysis of a three-arm randomized trial.
Scagliotti GV; De Marinis F; Rinaldi M; Crinò L; Gridelli C; Ricci S; Zhao YD; Liepa AM; Peterson P; Tonato M
J Thorac Oncol; 2009 Dec; 4(12):1568-71. PubMed ID: 20009911
[TBL] [Abstract][Full Text] [Related]
13. Randomized phase II trial of sequential chemotherapy in advanced non-small cell lung cancer (SWOG 9806): carboplatin/gemcitabine followed by paclitaxel or cisplatin/vinorelbine followed by docetaxel.
Edelman MJ; Clark JI; Chansky K; Albain K; Bhoopalam N; Weiss GR; Giguere JK; Kelly K; Crowley J; Gandara DR
Clin Cancer Res; 2004 Aug; 10(15):5022-6. PubMed ID: 15297403
[TBL] [Abstract][Full Text] [Related]
14. Vinorelbine plus gemcitabine followed by docetaxel versus carboplatin plus paclitaxel in patients with advanced non-small-cell lung cancer: a randomised, open-label, phase III study.
Kubota K; Kawahara M; Ogawara M; Nishiwaki Y; Komuta K; Minato K; Fujita Y; Teramukai S; Fukushima M; Furuse K;
Lancet Oncol; 2008 Dec; 9(12):1135-42. PubMed ID: 19013107
[TBL] [Abstract][Full Text] [Related]
15. Modest reductions in dose intensity and drug-induced neutropenia have no major impact on survival of patients with non-small cell lung cancer treated with platinum-doublet chemotherapy.
Brunetto AT; Carden CP; Myerson J; Faria AL; Ashley S; Popat S; O'Brien ME
J Thorac Oncol; 2010 Sep; 5(9):1397-403. PubMed ID: 20644495
[TBL] [Abstract][Full Text] [Related]
16. Triplet platinum-based combination sequential chemotherapy improves survival outcome and quality of life of advanced non-small cell lung cancer patients.
Chen LK; Liang Y; Yang QY; Xu F; Zhou NN; Xu GC; Liu GZ; Wei WD
Asian Pac J Cancer Prev; 2012; 13(5):1863-7. PubMed ID: 22901137
[TBL] [Abstract][Full Text] [Related]
17. Comparison of cisplatin- and carboplatin-based third-generation chemotherapy in 1,014 Chinese patients with advanced non-small-cell lung cancer.
Luo J; Leaw SJ; Xu Y; Zheng D
Med Oncol; 2011 Dec; 28(4):1418-24. PubMed ID: 20661668
[TBL] [Abstract][Full Text] [Related]
18. Non-platinum doublets were as effective as platinum-based doublets for chemotherapy-naïve advanced non-small-cell lung cancer in the era of third-generation agents.
Jiang J; Liang X; Zhou X; Huang R; Chu Z; Zhan Q
J Cancer Res Clin Oncol; 2013 Jan; 139(1):25-38. PubMed ID: 22864816
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the Efficacy between Pemetrexed plus Platinum and Non-Pemetrexed plus Platinum as First-Line Treatment in Patients with Wild-Type Epidermal Growth Factor Receptor Nonsquamous Non-Small Cell Lung Cancer: A Retrospective Analysis.
Kang EJ; Min KH; Hur GY; Lee SY; Shim JJ; Kang KH; Oh SC; Seo JH; Kim JS
Chemotherapy; 2016; 61(1):41-50. PubMed ID: 26517706
[TBL] [Abstract][Full Text] [Related]
20. A retrospective study: platinum-based induction chemotherapy combined with gemcitabine or paclitaxel for stage IIB-IIIA central non-small-cell lung cancer.
Lv C; Ma Y; Wu N; Yan S; Zheng Q; Sun Y; Li S; Fang J; Yang Y
World J Surg Oncol; 2013 Mar; 11():76. PubMed ID: 23517534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]